Officer sold ~$183K of Gilead Sciences
Scheduled in advanceLoading…
Traded May 15, 2026 · Filed May 18, 2026
Gilead Sciences's Chief Comm & Corp Aff Officer sold $1.11M of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,107,314
Shares × reported transaction price
8 days after results of May 7, 2026, 81 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $129.58 on May 15, 2026, 26% above its 52-week low and 17% below its high, after a 7% drop over the previous 30 trading days
52-week range $102.50 (May 16, 2025) to $155.80 (Feb 11, 2026), 51% of the way up, from 251 adjusted closes. 30 trading days earlier: $139.71 on Apr 2, 2026. Describes the past only, not a forecast
A WARN layoff notice covering 108 workers was filed in California on April 30, 2026.
From the official state WARN list, 15 days before the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Hepcludex on May 22, 2026, 7 days after this trade.
Biologic approved. Active ingredient: Bulevirtide-Gmod. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.5% | +2.3% | +0.2% |
| 30 days | -5.2% | +1.8% | -6.9% |
| 90 days | +6.5% | +5.3% | +1.1% |
Past results only. Not a forecast.
Officer sold ~$183K of Gilead Sciences
Scheduled in advanceOfficer sold ~$133K of Gilead Sciences
Scheduled in advanceOfficer sold ~$56K of Gilead Sciences
Scheduled in advance
